RCT | Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentaries:

Interim Analysis of Overall Survival in the monarchE Trial – The ASCO Post

Commentary on Twitter

?Adjuvant abemaciclib reduces the risk of recurrence in patients with hormone receptor (+), HER2(-), node-positive, high-risk early #BreastCancer
?Serious AEs 15·5%
?Most common G 3–4 AE neutropenia 19·6%@OncoAlert @SABCSSanAntonio #SABCS #SABCS2022 https://t.co/KY2NskvB9B pic.twitter.com/2uauz6hPlO

— Yüksel Ürün (@DrYukselUrun) December 6, 2022